IS5887A - Interferón-beta bræðsluprótín og notkun þeirra - Google Patents

Interferón-beta bræðsluprótín og notkun þeirra

Info

Publication number: IS5887A
Authority: IS; Iceland
Prior art keywords: interferon; beta; fusion proteins; beta fusion; polypeptide
Prior art date: 1998-10-16

Application number

IS5887A

Other languages

English (en)

Inventor

Whitty Adrian

Runkel Laura

Brickelmaier Margot

Hochman Paula

Original Assignee

Biogen Idec Ma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-16

Filing date

2001-03-14

Publication date

2001-03-14

2001-03-14 Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.

2001-03-14 Publication of IS5887A publication Critical patent/IS5887A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Toxicology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Virology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)

IS5887A 1998-10-16 2001-03-14 Interferón-beta bræðsluprótín og notkun þeirra IS5887A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10449198P	1998-10-16	1998-10-16
US12023799P	1999-02-16	1999-02-16
PCT/US1999/024200 WO2000023472A2 (en)	1998-10-16	1999-10-15	Interferon-beta fusion proteins and uses

Publications (1)

Publication Number	Publication Date
IS5887A true IS5887A (is)	2001-03-14

Family

ID=26801613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5887A IS5887A (is)	1998-10-16	2001-03-14	Interferón-beta bræðsluprótín og notkun þeirra

Country Status (28)

Country	Link
US (3)	US6800735B2 (is)
EP (1)	EP1121382B9 (is)
JP (2)	JP4761621B2 (is)
KR (1)	KR100767649B1 (is)
CN (1)	CN100480266C (is)
AT (1)	ATE327254T1 (is)
AU (1)	AU766190B2 (is)
BR (1)	BR9915548A (is)
CA (1)	CA2343094A1 (is)
CY (1)	CY1105173T1 (is)
CZ (1)	CZ300762B6 (is)
DE (1)	DE69931507T2 (is)
DK (1)	DK1121382T3 (is)
EA (1)	EA005005B1 (is)
EE (1)	EE05111B1 (is)
ES (1)	ES2265693T3 (is)
HK (1)	HK1042098B (is)
HU (1)	HUP0200414A2 (is)
IL (2)	IL142350A0 (is)
IS (1)	IS5887A (is)
MX (1)	MXPA01003790A (is)
NO (1)	NO20011861L (is)
NZ (1)	NZ510559A (is)
PL (1)	PL200586B1 (is)
PT (1)	PT1121382E (is)
SK (1)	SK287491B6 (is)
TR (1)	TR200101087T2 (is)
WO (1)	WO2000023472A2 (is)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2313028A1 (en) *	1997-12-01	1999-06-10	Cfy Biomedicals, Inc.	Multivalent recombinant antibodies for treating hrv infections
HU229888B1 (en)	1998-10-16	2014-11-28	Biogen Idec Ma Inc Cambridge	Polymer conjugates of interferon betha-1a and uses
EP1121382B9 (en) *	1998-10-16	2007-07-04	Biogen Idec MA Inc.	Interferon-beta fusion proteins and uses
US20030035798A1 (en) *	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
US7431921B2 (en)	2000-04-14	2008-10-07	Maxygen Aps	Interferon beta-like molecules
US7144574B2 (en)	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US6531122B1 (en)	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
US6697363B1 (en)	2000-06-28	2004-02-24	Alcatel Canada Inc.	Method and apparatus for longest matching prefix determination in a communication network
AU2002212107A1 (en) *	2000-11-02	2002-05-15	Maxygen Aps	New multimeric interferon beta polypeptides
ATE359808T1 (de) *	2000-12-06	2007-05-15	Applied Research Systems	Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE50204952D1 (de) *	2001-02-01	2005-12-22	Roche Diagnostics Gmbh	Verfahren zur herstellung von rekombinantem trypsin
ATE432288T1 (de)	2001-02-27	2009-06-15	Maxygen Aps	Neue interferon-beta-ähnliche moleküle
MXPA03008310A (es) *	2001-03-15	2003-12-11	Merck Patent Gmbh	Interferon beta modificado con inmunogenicidad reducida.
US20030138440A1 (en) *	2001-07-19	2003-07-24	Fang Fang	Multimeric proteins and methods of making and using same
WO2003066165A1 (en) *	2002-02-06	2003-08-14	Ares Trading S.A.	Tumor necrosis factor combined with interferon in demyelinating diseases
NZ538217A (en) *	2002-07-17	2007-04-27	Biogen Idec Inc	Beta interferon when used to treat proteinuria, glomerular cell proliferation and inflammation
AU2003254641A1 (en) *	2002-08-28	2004-03-19	Maxygen Aps	Interferon beta-like molecules for treatment of cancer
EP1539960B1 (en) *	2002-09-09	2010-04-28	Hanall Pharmaceutical Co., Ltd.	Protease-resistant modified interferon alpha polypeptides
WO2004028472A2 (en) *	2002-09-27	2004-04-08	Biogen Idec Ma Inc.	THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
WO2004031352A2 (en) *	2002-10-01	2004-04-15	Xencor, Inc.	Interferon variants with improved properties
TW200510532A (en)	2003-07-15	2005-03-16	Chugai Pharmaceutical Co Ltd	IgM production by transformed cell and method of quantifying the same
EP1670931A2 (en) *	2003-09-05	2006-06-21	GTC Biotherapeutics, Inc.	Method for the production of fusion proteins in transgenic mammal milk
ATE518888T1 (de)	2003-10-09	2011-08-15	Chugai Pharmaceutical Co Ltd	Stabilisierte lösung mit hoher igm-konzentration
US8110665B2 (en)	2003-11-13	2012-02-07	Hanmi Holdings Co., Ltd.	Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005047337A1 (en)	2003-11-13	2005-05-26	Hanmi Pharmaceutical Co., Ltd.	A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
JP2007519422A (ja)	2004-02-02	2007-07-19	アンブレツクス・インコーポレイテツド	修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
EP1734988A4 (en) *	2004-03-01	2009-08-05	Enzon Pharmaceuticals Inc	INTERFERON BETA-polymer
WO2005120540A2 (en) *	2004-06-09	2005-12-22	Schering Aktiengesellschaft	Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
US7670595B2 (en) *	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
CN107028760B (zh) *	2005-01-12	2019-11-01	比奥根Ma公司	运输干扰素-β的方法
EA013816B1 (ru)	2005-09-01	2010-08-30	Арес Трейдинг С.А.	Лечение неврита зрительного нерва
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en)	2006-02-03	2014-06-24	Prolor Biotech, Llc	Long-acting coagulation factors and methods of producing same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8450269B2 (en)	2006-02-03	2013-05-28	Prolor Biotech Ltd.	Long-acting growth hormone and methods of producing same
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en)	2006-02-03	2016-10-04	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8476234B2 (en)	2006-02-03	2013-07-02	Prolor Biotech Inc.	Long-acting coagulation factors and methods of producing same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
WO2007092252A2 (en) *	2006-02-03	2007-08-16	Modigene Inc	Long-acting polypeptides and methods of producing same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US20080038224A1 (en) *	2006-03-28	2008-02-14	Thierry Guyon	Modified interferon-beta (IFN-beta) polypeptides
JO3324B1 (ar)	2006-04-21	2019-03-13	Amgen Inc	مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2007253254B2 (en)	2006-05-24	2013-01-17	Merck Serono Sa	Cladribine regimen for treating multiple sclerosis
US8414897B1 (en) *	2006-10-02	2013-04-09	The Uab Research Foundation	Pathway for Th-17 cell development and methods utilizing same
FR2907454B1 (fr) *	2006-10-18	2009-01-23	Biomethodes Sa	Variants ameliores de l'interferon beta humain
NZ580686A (en)	2007-05-02	2012-11-30	Ambrx Inc	Modified interferon beta polypeptides and their uses
CA2697032C (en)	2007-08-22	2021-09-14	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
AU2008302111B2 (en) *	2007-09-21	2014-04-24	The Regents Of The University Of California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100203009A1 (en) *	2007-10-02	2010-08-12	The Uab Research Foundation	Pathway for Th-17 Cell Development and Methods Utilizing Same
EP2203180B1 (en) *	2007-10-22	2012-11-21	Merck Serono S.A.	Single ifn-beta fused to a mutated igg fc fragment
EP2247743B1 (en)	2008-02-08	2016-04-06	Ambrx, Inc.	Modified leptin polypeptides and their uses
CN102112493B (zh)	2008-07-23	2015-04-01	韩美科学株式会社	包含具有三个官能性末端的非肽基聚合物的多肽复合物
UA103774C2 (uk)	2008-07-23	2013-11-25	Амбркс, Інк.	Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
BRPI1006141B8 (pt)	2009-01-12	2021-05-25	Cytomx Therapeutics Llc	composições de anticorpo modificado, métodos para preparar e usar as mesmas
CA2753294A1 (en)	2009-02-23	2010-08-26	Cytomx Therapeutics, Inc.	Proproteins and methods of use thereof
EA201171259A1 (ru)	2009-04-22	2012-05-30	Мерк Патент Гмбх	Антительные гибридные белки с модифицированными сайтами связывания fcrn
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
JP2013515081A (ja)	2009-12-21	2013-05-02	アンブルックス，インコーポレイテッド	修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
NZ600361A (en)	2009-12-21	2014-06-27	Ambrx Inc	Modified bovine somatotropin polypeptides and their uses
HUE025878T2 (en) *	2010-02-12	2016-05-30	Biogen Ma Inc	Neuroprotection in demyelinating diseases
WO2011106234A1 (en)	2010-02-25	2011-09-01	Provasculon, Inc.	Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AR080993A1 (es) *	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
EP2717894B1 (en) *	2011-06-07	2018-01-24	Mesoblast International Sàrl	Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
DK2762489T3 (en)	2011-10-01	2018-07-02	Glytech Inc	GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
SG11201401518TA (en)	2011-10-28	2014-05-29	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof
MX2014012625A (es)	2012-04-19	2015-05-15	Opko Biolog Ltd	Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
US9783589B2 (en) *	2012-08-13	2017-10-10	Immungene Inc	Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
CN112661863A (zh)	2012-11-20	2021-04-16	奥普科生物制品有限公司	通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US9803021B2 (en)	2012-12-07	2017-10-31	The Regents Of The University Of California	CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
KR102073748B1 (ko)	2013-01-31	2020-02-05	한미약품 주식회사	재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
DK2982686T3 (en)	2013-03-29	2018-10-08	Glytech Inc	POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
ES2938708T3 (es)	2013-04-29	2023-04-14	Teva Pharmaceuticals Australia Pty Ltd	Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en)	2013-04-29	2021-09-14	Teva Pharmaceuticals Australia Pty Ltd	Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN104151420A (zh) *	2013-05-15	2014-11-19	复旦大学	长效干扰素及其制备方法和用途
US10093745B2 (en)	2013-05-29	2018-10-09	The Regents Of The University Of California	Anti-CSPG4 fusions with interferon for the treatment of malignancy
AR096891A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
WO2015091144A1 (en)	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Improved recombinant polypeptide production methods
UA119352C2 (uk)	2014-05-01	2019-06-10	Тева Фармасьютикалз Острейліа Пті Лтд	Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
SG11201703251TA (en)	2014-10-29	2017-05-30	Teva Pharmaceuticals Australia Pty Ltd	INTERFERON α2B VARIANTS
CA3228939A1 (en)	2015-06-19	2016-12-22	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
UA123053C2 (uk)	2015-06-24	2021-02-10	Ф. Хоффманн-Ля Рош Аг	Антитіло до рецептора трансферину зі спеціально підібраною афінністю
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja)	2015-10-02	2020-03-04	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
WO2017194783A1 (en) *	2016-05-13	2017-11-16	Orionis Biosciences Nv	Targeted mutant interferon-beta and uses thereof
US11976106B2 (en)	2016-07-11	2024-05-07	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
JP2023512951A (ja) *	2020-01-23	2023-03-30	ジェネクシン・インコーポレイテッド	Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途
WO2021203098A2 (en) *	2020-04-03	2021-10-07	The University Of North Carolina At Chapel Hill	Binding proteins useful against ace2-targeted viruses
US20230293679A1 (en) *	2020-07-01	2023-09-21	Institute Of Biophysics, Chinese Academy Of Sciences	Construction and application of fusion protein vaccine platform

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3359030A (en) *	1966-12-16	1967-12-19	Newman George	Bumper guard assembly
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4414147A (en)	1981-04-17	1983-11-08	Massachusetts Institute Of Technology	Methods of decreasing the hydrophobicity of fibroblast and other interferons
IT1167610B (it) *	1982-01-19	1987-05-13	Cetus Corp	Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4609546A (en)	1982-06-24	1986-09-02	Japan Chemical Research Co., Ltd.	Long-acting composition
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
GB8412564D0 (en) *	1984-05-17	1984-06-20	Searle & Co	Structure and properties
JP2524586B2 (ja)	1985-06-26	1996-08-14	シタスコーポレイション	ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) *	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) *	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
JP2514950B2 (ja)	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
JPS63152393A (ja)	1986-07-03	1988-06-24	Takeda Chem Ind Ltd	グリコシル誘導体
US4868802A (en) *	1986-07-28	1989-09-19	Kabushiki Kaisha Toshiba	Magnetooptic recording and erasing head which performs biasing, tracking and focusing
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
CA1340810C (en)	1988-03-31	1999-11-02	Motoo Yamasaki	Polypeptide derivatives of human granulocyte colony stimulating factor
WO1990005534A1 (en)	1988-11-23	1990-05-31	Genentech, Inc.	Polypeptide derivatives
JP2989002B2 (ja)	1988-12-22	1999-12-13	キリン―アムジエン・インコーポレーテツド	化学修飾顆粒球コロニー刺激因子
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
JPH04218000A (ja)	1990-02-13	1992-08-07	Kirin Amgen Inc	修飾ポリペプチド
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
SG89295A1 (en)	1991-03-15	2002-06-18	Amgen Inc	Pegylation of polypeptides
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5281698A (en)	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en)	1991-12-19	1993-06-24	Baylor College Of Medicine	Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en)	1992-06-17	1994-01-03	Amgen Inc	Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5255519A (en)	1992-08-14	1993-10-26	Millennium Technologies, Inc.	Method and apparatus for increasing efficiency and productivity in a power generation cycle
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
WO1994005332A2 (en)	1992-09-01	1994-03-17	Berlex Laboratories, Inc.	Glycolation of glycosylated macromolecules
US5298410A (en)	1993-02-25	1994-03-29	Sterling Winthrop Inc.	Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en)	1993-10-06	1999-02-23	Amgen Inc.	Stable protein: phospholipid compositions and methods
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
NZ276943A (en)	1993-11-10	1998-02-26	Schering Corp Substituted For	Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5951974A (en)	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
PT726778E (pt)	1994-02-08	2001-12-28	Amgen Inc	Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US5545723A (en)	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
GB9415379D0 (en) *	1994-07-29	1994-09-21	Smithkline Beecham Plc	Novel compounds
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5738846A (en)	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
WO1996017929A1 (en)	1994-12-07	1996-06-13	Novo Nordisk A/S	Polypeptide with reduced allergenicity
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0154850B1 (ko) *	1995-10-09	1998-10-15	김광호	바이씨모스 및 그의 제조방법
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US5723125A (en) *	1995-12-28	1998-03-03	Tanox Biosystems, Inc.	Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5747639A (en)	1996-03-06	1998-05-05	Amgen Boulder Inc.	Use of hydrophobic interaction chromatography to purify polyethylene glycols
AU5773798A (en)	1997-01-29	1998-08-18	Polymasc Pharmaceuticals Plc	Pegylation process
US5990237A (en)	1997-05-21	1999-11-23	Shearwater Polymers, Inc.	Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU751898B2 (en)	1997-07-14	2002-08-29	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
US6180095B1 (en)	1997-12-17	2001-01-30	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en)	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
US5981709A (en)	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en)	1997-12-30	1999-10-12	Enzon, Inc.	Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
DE69939033D1 (de)	1998-03-12	2008-08-14	Nektar Therapeutics Al Corp	Verfahren zur Herstellung von Polymerkonjugaten
NZ507456A (en)	1998-04-28	2003-10-31	Applied Research Systems	Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated
US6703381B1 (en)	1998-08-14	2004-03-09	Nobex Corporation	Methods for delivery therapeutic compounds across the blood-brain barrier
HU229888B1 (en) *	1998-10-16	2014-11-28	Biogen Idec Ma Inc Cambridge	Polymer conjugates of interferon betha-1a and uses
EP1121382B9 (en) *	1998-10-16	2007-07-04	Biogen Idec MA Inc.	Interferon-beta fusion proteins and uses
JP2003527090A (ja)	1999-08-27	2003-09-16	マキシゲン・エイピーエス	新規なインターフェロンベータ様分子
DK1259562T3 (da)	1999-12-22	2006-04-18	Nektar Therapeutics Al Corp	Sterisk hindrede derivater af vandoplöselige polymerer
US20080033818A1 (en)	2005-03-17	2008-02-07	Inc2 Webcom Ltd.	Real time interactive response system and methods

1999
- 1999-10-15 EP EP99956574A patent/EP1121382B9/en not_active Expired - Lifetime
- 1999-10-15 NZ NZ510559A patent/NZ510559A/en not_active IP Right Cessation
- 1999-10-15 CZ CZ20011330A patent/CZ300762B6/cs not_active IP Right Cessation
- 1999-10-15 MX MXPA01003790A patent/MXPA01003790A/es not_active IP Right Cessation
- 1999-10-15 JP JP2000577197A patent/JP4761621B2/ja not_active Expired - Fee Related
- 1999-10-15 EA EA200100447A patent/EA005005B1/ru not_active IP Right Cessation
- 1999-10-15 CA CA002343094A patent/CA2343094A1/en not_active Abandoned
- 1999-10-15 BR BR9915548-6A patent/BR9915548A/pt not_active Application Discontinuation
- 1999-10-15 PT PT99956574T patent/PT1121382E/pt unknown
- 1999-10-15 SK SK510-2001A patent/SK287491B6/sk not_active IP Right Cessation
- 1999-10-15 DK DK99956574T patent/DK1121382T3/da active
- 1999-10-15 AT AT99956574T patent/ATE327254T1/de active
- 1999-10-15 WO PCT/US1999/024200 patent/WO2000023472A2/en active IP Right Grant
- 1999-10-15 DE DE69931507T patent/DE69931507T2/de not_active Expired - Lifetime
- 1999-10-15 EE EEP200100223A patent/EE05111B1/xx not_active IP Right Cessation
- 1999-10-15 CN CNB998122130A patent/CN100480266C/zh not_active Expired - Fee Related
- 1999-10-15 ES ES99956574T patent/ES2265693T3/es not_active Expired - Lifetime
- 1999-10-15 AU AU13158/00A patent/AU766190B2/en not_active Ceased
- 1999-10-15 HU HU0200414A patent/HUP0200414A2/hu unknown
- 1999-10-15 KR KR1020017004797A patent/KR100767649B1/ko not_active IP Right Cessation
- 1999-10-15 PL PL347932A patent/PL200586B1/pl not_active IP Right Cessation
- 1999-10-15 TR TR2001/01087T patent/TR200101087T2/xx unknown
- 1999-10-15 IL IL14235099A patent/IL142350A0/xx active IP Right Grant
2001
- 2001-03-14 IS IS5887A patent/IS5887A/is unknown
- 2001-04-01 IL IL142350A patent/IL142350A/en not_active IP Right Cessation
- 2001-04-11 US US09/832,659 patent/US6800735B2/en not_active Expired - Fee Related
- 2001-04-11 NO NO20011861A patent/NO20011861L/no unknown
2002
- 2002-05-24 HK HK02103895.8A patent/HK1042098B/zh not_active IP Right Cessation
2004
- 2004-06-15 US US10/868,673 patent/US7527946B2/en not_active Expired - Fee Related
2006
- 2006-08-24 CY CY20061101194T patent/CY1105173T1/el unknown
2009
- 2009-03-18 US US12/406,387 patent/US20090286958A1/en not_active Abandoned
2010
- 2010-07-22 JP JP2010165349A patent/JP2010268810A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MXPA01003790A (es)	2002-09-18
ES2265693T3 (es)	2007-02-16
CN100480266C (zh)	2009-04-22
US20090286958A1 (en)	2009-11-19
IL142350A0 (en)	2002-03-10
TR200101087T2 (tr)	2001-09-21
KR20010085932A (ko)	2001-09-07
JP4761621B2 (ja)	2011-08-31
US6800735B2 (en)	2004-10-05
AU766190B2 (en)	2003-10-09
BR9915548A (pt)	2001-08-14
JP2010268810A (ja)	2010-12-02
EP1121382B9 (en)	2007-07-04
DE69931507T2 (de)	2007-01-11
US20020155547A1 (en)	2002-10-24
PT1121382E (pt)	2006-10-31
ATE327254T1 (de)	2006-06-15
JP2002527100A (ja)	2002-08-27
SK5102001A3 (en)	2003-03-04
KR100767649B1 (ko)	2007-10-17
PL200586B1 (pl)	2009-01-30
US20050214253A1 (en)	2005-09-29
NZ510559A (en)	2003-12-19
IL142350A (en)	2007-07-04
HUP0200414A2 (en)	2002-06-29
EA200100447A1 (ru)	2001-10-22
CY1105173T1 (el)	2010-03-03
EE200100223A (et)	2002-06-17
WO2000023472A3 (en)	2000-08-31
CZ20011330A3 (cs)	2001-09-12
CA2343094A1 (en)	2000-04-27
SK287491B6 (sk)	2010-11-08
CN1333785A (zh)	2002-01-30
DE69931507D1 (de)	2006-06-29
DK1121382T3 (da)	2006-11-13
HK1042098A1 (en)	2002-08-02
EE05111B1 (et)	2008-12-15
EP1121382A2 (en)	2001-08-08
PL347932A1 (en)	2002-04-22
HK1042098B (zh)	2009-10-30
AU1315800A (en)	2000-05-08
EP1121382B1 (en)	2006-05-24
CZ300762B6 (cs)	2009-08-05
NO20011861D0 (no)	2001-04-11
NO20011861L (no)	2001-06-13
EA005005B1 (ru)	2004-10-28
US7527946B2 (en)	2009-05-05
WO2000023472A2 (en)	2000-04-27

Publication	Publication Date	Title
IS5887A (is)	2001-03-14	Interferón-beta bræðsluprótín og notkun þeirra
ES2149149T1 (es)	2000-11-01	Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
TR199600357A2 (tr)	1996-11-21	Rekombinant simanlik (Ob) proteinleri.
DK0489116T3 (da)	1994-05-02	Fusionsproteiner omfattende GM-CSF og IL-3
TR199501669A1 (tr)	1997-03-21	Peptid ve proteinlerin aerosol formülasyonlari.
DK1490386T3 (da)	2008-12-15	Nyt polypeptid og nukleinsyrer kodende for dette
DK1025124T3 (da)	2008-10-06	Human interferon-alfa-analoge med lav toksicitet
NZ521396A (en)	2004-06-25	Fusion proteins comprising two or more Neisseria polypeptides
DK0954588T3 (da)	2007-05-14	OB fusionsprotein-sammensætninger og fremgangsmåder
HK1036475A1 (en)	2002-01-04	Erythropoietin analog-human serum albumin fusion protein
NO20100324L (no)	2000-12-28	Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
NO995891L (no)	2000-02-01	LH-RH peptidanaloger, anvendelser og farmasoeytiske blandinger inneholdende disse
DK1025236T3 (da)	2005-10-24	Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
NO995062L (no)	1999-12-14	<Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som koder for samme
EP1739090A3 (en)	2009-04-08	Interferon-beta fusion proteins and uses
NO20005081D0 (no)	2000-10-09	Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
NO20005547D0 (no)	2000-11-03	Myelinbasiske proteinpeptider og anvendelser derav
DK0490383T3 (da)	1997-02-17	Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
DK0938555T3 (da)	2005-05-23	Konstruktioner og komplekser af cyclin E
DK0845040T3 (da)	2005-09-05	Plastidindre kappemembranmålretningspolypeptider; fremstilling og anvendelse deraf
ID16711A (id)	1997-11-06	Protein-protein obese (ob) rekombinan